Spice drugs as a new trend: Mode of action, identification and legislation

被引:259
作者
Vardakou, I. [1 ]
Pistos, C. [1 ]
Spiliopoulou, Ch. [1 ]
机构
[1] Univ Athens, Dept Forens Med & Toxicol, Sch Med, Athens 11527, Greece
关键词
Spice; Synthetic cannabinoids; JWH-018; HU-210; CP-47,497; RECEPTOR-BINDING; CANNABINOID CB1; PHARMACOLOGY; CLASSIFICATION; HU210;
D O I
10.1016/j.toxlet.2010.06.002
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The present review highlights the existing monitoring and legislation status of synthetic cannabinoids in "Spice" products and alert research community about the identification and risk assessment problems of these compounds. Available data were collected by various literature search engines All valuable information about psychoactive properties, safety profile, clinical data and detection problems for synthetic cannabinoids and their use as "herbal highs" were managed to spot and summarise. "Spice" contains synthetic cannabinoids that bind to cannabinnoid-like receptors and they are stronger than natural cannabis Chronic abuse of "Spice" has linked with signs of addiction syndrome and withdrawal symptoms similar to syndromes observed in cannabis abuse. These cannabinoids can be considered as new products to be added to the list of "designer drugs". Although it remains unclear where and how the actual production of the herbal mixtures takes place, it is evident that producers are purposely risk the health of consumers to skim high profits Only recently a number of countries in Europe, as well as in US and Canada banned the use of these substances The difficulty in identification of related compounds leads to the necessity for the availability of reference standards in order to aid toxicological analyses (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 38 条
[1]  
Advisory Council on the Misuse of Drugs (ACMD), 2009, CONS MAJ CANN AG
[2]  
[Anonymous], 2001, Goodman and Gilman's Pharmacological Basis of Therapeutics, V10th
[3]   Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding [J].
Aung, MM ;
Griffin, G ;
Huffman, JW ;
Wu, MJ ;
Keel, C ;
Yang, B ;
Showalter, VM ;
Abood, ME ;
Martin, BR .
DRUG AND ALCOHOL DEPENDENCE, 2000, 60 (02) :133-140
[4]   'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? [J].
Auwaerter, Volker ;
Dresen, Sebastian ;
Weinmann, Wolfgang ;
Mueller, Michael ;
Puetz, Michael ;
Ferreiros, Nerea .
JOURNAL OF MASS SPECTROMETRY, 2009, 44 (05) :832-837
[5]  
Chin CN, 1999, J PHARMACOL EXP THER, V291, P837
[6]  
COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218
[7]  
COMPTON DR, 1992, J PHARMACOL EXP THER, V260, P201
[8]   HU210-Induced Downregulation in Cannabinoid CB1 Receptor Binding Strongly Correlates with Body Weight Loss in the Adult Rat [J].
Dalton, Victoria S. ;
Wang, Hongqin ;
Zavitsanou, Katerina .
NEUROCHEMICAL RESEARCH, 2009, 34 (07) :1343-1353
[9]  
*EMCDDA, 2009, EARL WARN SYST UND S
[10]  
*EMCDDA EUR, 2008, 2005387JHA EMCDDA EU